Matches in SemOpenAlex for { <https://semopenalex.org/work/W2574173779> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2574173779 abstract "e19088 Background: Gefitinib shows outstandingly high rates of clinical benefit in NSCLC pts with EGFR mutation and is better tolerable than conventional chemotherapy, therefore its consideration for the upfront treatment is warranted. Methods: 21 chemonaive pts with inoperable NSCLC were selected based on the presence of EGFR mutation in the tumor DNA (16 exon 19 deletions and 5 T858G substitutions). All cases were adenocarcinomas; median age: 60 years (range: 36 - 81 years); males/females: 6/15; ECOG PS 0/1/2/3: 4/10/6/1. Gefitinib was administered at conventional dose 250 mg/d. Results: The overall disease control rate was 95% (CR: 2/21; PR: 11/21; SD: 7/21). Complete responses were observed only in tumors with exon 19 deletion, whereas the only patient with disease progression had codon 858 substitution. Grade III toxicity occurred only in 3 pts (2: skin rash; 1: diarrhea). Time to disease progression ranged from 2+ to 18 months. 3 pts achieved an operable status of the disease upon the treatment, and therefore were subjected to surgical intervention followed by adjuvant gefitinib therapy. Conclusions: Gefitinib may be considered as the treatment of choice for chemonaive EGFR mutation-containing inoperable NSCLC. No significant financial relationships to disclose." @default.
- W2574173779 created "2017-01-26" @default.
- W2574173779 creator A5005009745 @default.
- W2574173779 creator A5035686789 @default.
- W2574173779 creator A5039700060 @default.
- W2574173779 creator A5046042894 @default.
- W2574173779 creator A5055784087 @default.
- W2574173779 creator A5056604741 @default.
- W2574173779 creator A5063114141 @default.
- W2574173779 creator A5079565112 @default.
- W2574173779 creator A5080944582 @default.
- W2574173779 creator A5085241792 @default.
- W2574173779 date "2009-05-20" @default.
- W2574173779 modified "2023-09-26" @default.
- W2574173779 title "First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib" @default.
- W2574173779 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e19088" @default.
- W2574173779 hasPublicationYear "2009" @default.
- W2574173779 type Work @default.
- W2574173779 sameAs 2574173779 @default.
- W2574173779 citedByCount "0" @default.
- W2574173779 crossrefType "journal-article" @default.
- W2574173779 hasAuthorship W2574173779A5005009745 @default.
- W2574173779 hasAuthorship W2574173779A5035686789 @default.
- W2574173779 hasAuthorship W2574173779A5039700060 @default.
- W2574173779 hasAuthorship W2574173779A5046042894 @default.
- W2574173779 hasAuthorship W2574173779A5055784087 @default.
- W2574173779 hasAuthorship W2574173779A5056604741 @default.
- W2574173779 hasAuthorship W2574173779A5063114141 @default.
- W2574173779 hasAuthorship W2574173779A5079565112 @default.
- W2574173779 hasAuthorship W2574173779A5080944582 @default.
- W2574173779 hasAuthorship W2574173779A5085241792 @default.
- W2574173779 hasConcept C104317684 @default.
- W2574173779 hasConcept C121608353 @default.
- W2574173779 hasConcept C126322002 @default.
- W2574173779 hasConcept C143998085 @default.
- W2574173779 hasConcept C2776256026 @default.
- W2574173779 hasConcept C2778087573 @default.
- W2574173779 hasConcept C2779438470 @default.
- W2574173779 hasConcept C2780580887 @default.
- W2574173779 hasConcept C501734568 @default.
- W2574173779 hasConcept C502942594 @default.
- W2574173779 hasConcept C54355233 @default.
- W2574173779 hasConcept C71924100 @default.
- W2574173779 hasConcept C86803240 @default.
- W2574173779 hasConceptScore W2574173779C104317684 @default.
- W2574173779 hasConceptScore W2574173779C121608353 @default.
- W2574173779 hasConceptScore W2574173779C126322002 @default.
- W2574173779 hasConceptScore W2574173779C143998085 @default.
- W2574173779 hasConceptScore W2574173779C2776256026 @default.
- W2574173779 hasConceptScore W2574173779C2778087573 @default.
- W2574173779 hasConceptScore W2574173779C2779438470 @default.
- W2574173779 hasConceptScore W2574173779C2780580887 @default.
- W2574173779 hasConceptScore W2574173779C501734568 @default.
- W2574173779 hasConceptScore W2574173779C502942594 @default.
- W2574173779 hasConceptScore W2574173779C54355233 @default.
- W2574173779 hasConceptScore W2574173779C71924100 @default.
- W2574173779 hasConceptScore W2574173779C86803240 @default.
- W2574173779 hasLocation W25741737791 @default.
- W2574173779 hasOpenAccess W2574173779 @default.
- W2574173779 hasPrimaryLocation W25741737791 @default.
- W2574173779 hasRelatedWork W1669238269 @default.
- W2574173779 hasRelatedWork W2065543621 @default.
- W2574173779 hasRelatedWork W2113451729 @default.
- W2574173779 hasRelatedWork W2120200191 @default.
- W2574173779 hasRelatedWork W2154302986 @default.
- W2574173779 hasRelatedWork W2261901203 @default.
- W2574173779 hasRelatedWork W2283855024 @default.
- W2574173779 hasRelatedWork W2321260730 @default.
- W2574173779 hasRelatedWork W2324892749 @default.
- W2574173779 hasRelatedWork W2328117675 @default.
- W2574173779 hasRelatedWork W2538379746 @default.
- W2574173779 hasRelatedWork W2563308044 @default.
- W2574173779 hasRelatedWork W2589252540 @default.
- W2574173779 hasRelatedWork W2591254499 @default.
- W2574173779 hasRelatedWork W2809065633 @default.
- W2574173779 hasRelatedWork W2890947050 @default.
- W2574173779 hasRelatedWork W3131335352 @default.
- W2574173779 hasRelatedWork W2035047470 @default.
- W2574173779 hasRelatedWork W2311778681 @default.
- W2574173779 hasRelatedWork W3029339393 @default.
- W2574173779 isParatext "false" @default.
- W2574173779 isRetracted "false" @default.
- W2574173779 magId "2574173779" @default.
- W2574173779 workType "article" @default.